Cadila Healthcare rose 1.86% to Rs 1,692.10 at 9:43 IST on BSE after the company said it has purchased 50% shares of Zydus BSV Pharma from Bharat Serums and Vaccines and now Zydus BSV has become 100% subsidiary of Cadila Healthcare.
The announcement was made after market hours yesterday, 26 March 2015.
Meanwhile, the S&P BSE Sensex was up 46.85 points or 0.17% at 27,504.43.
On BSE, so far 6,020 shares were traded in the counter as against average daily volume of 21,000 shares in the past two weeks.
The stock hit a high of Rs 1,721 and a low of Rs 1,686.65 so far during the day.
On a consolidated basis, Cadila Healthcare's net profit rose 51.6% to Rs 281.91 crore on 17.5% growth in net sales to Rs 2159.54 crore in Q3 December 2014 over Q3 December 2013.
Also Read
Cadila Healthcare is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.
Powered by Capital Market - Live News